Antibody-Functionalized Nanoformulations for Targeted Therapy of Colorectal Cancer: A Systematic Review
MetadataShow full item record
AuthorCepero Martín, Ana; Luque, Cristina; Cabeza Montilla, Laura; Perazzoli, Gloria; Quiñonero Muñoz, Francisco José; Mesas Hernández, Cristina; Melguizo Alonso, Consolación; Prados Salazar, José Carlos
Dove Medical Press
NanoformulationColon carcinomaMonoclonal antibody5-fluorouracilTargeted therapy
Cepero A... [et al.]. Antibody-Functionalized Nanoformulations for Targeted Therapy of Colorectal Cancer: A Systematic Review. Int J Nanomedicine. 2022;17:5065-5080 [https://doi.org/10.2147/IJN.S368814]
SponsorshipMinisterio de Educacion y Formacion Profesional (Spain) FPU17/02977 FPU19/04112; Spanish Government PI20-00284; Junta de Andalucia A-CTS-666-UGR20 P20_00540 B-CTS-122-UGR20 PYC20-RE-035 UGR; European Commission Instituto de Salud Carlos III European Commission PI19/01478-FEDER
The failure of chemotherapeutic treatment in colorectal cancer (CRC), the second most mortal cancer worldwide, is associated with several drug limitations, such as non-selective distribution, short half-life, and development of multiple resistances. One of the most promising strategies in CRC therapy is the development of delivery systems based on nanomaterials that can transport antitumor agents to the tumor site more efficiently, increasing accumulation within the tumor and thus the antitumor effect. In addition to taking advantage of the increased permeability and retention effect (EPR) of solid tumors, these nanoformulations can be conjugated with monoclonal antibodies that recognize molecular markers that are specifically over-expressed on CRC cells. Active targeting of nanoformulations reduces the adverse effects associated with the cytotoxic activity of drugs in healthy tissues, which will be of interest for improving the quality of life of cancer patients in the future. This review focuses on in vitro and in vivo studies of drug delivery nanoformulations functionalized with monoclonal antibodies for targeted therapy of CRC.